REGULATORY AND METHODOLOGICAL ASPECTS OF STUDYING ALLERGENIC PROPERTIES OF NEW MEDICINES AT THE PRECLINICAL STAGE
Autor: | K. L. Kryshen, A. E. Katelnikova, A. A. Muzhikyan, M. N. Маkarova, V. G. Makarov |
---|---|
Jazyk: | ruština |
Rok vydání: | 2018 |
Předmět: | |
Zdroj: | Регуляторные исследования и экспертиза лекарственных средств, Vol 8, Iss 1, Pp 44-55 (2018) |
Druh dokumentu: | article |
ISSN: | 3034-3062 3034-3453 1991-2919 |
DOI: | 10.30895/1991-2919-2018-8-1-44-55 |
Popis: | The assessment of allergic risk at the preclinical stage of drug development has been a debatable issue due to the integration of national requirements for medicines authorisation with those of the Eurasian Economic Union (EAEU). The article summarises mechanisms and factors involved in the development of drug hypersensitivity, as well as the main national and foreign regulatory requirements. It also cites the results of allergic risk assessment studies involving standard guinea pig tests, such as systemic anaphylactic reactions and active cutaneous anaphylaxis, for a number of medicines with the molecular weight of the active substance of more than 1000 Da and less than 1000 Da. Data analysis confirms that the number of positive reactions for high molecular weight compounds (>1000 Da) is significantly higher than the number of positive reactions for low molecular weight compounds ( |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |
Pro tento záznam nejsou dostupné žádné jednotky.